New Online Learning Tool Fills the Knowledge Gap on Botulinum Toxin Type B for Cervical Dystonia

Malvern, Pennsylvania (ots/PRNewswire) -

- Solstice Neurosciences, Inc. Launches a Self-Guided Lesson as
Prep for In-Person Workshops

In recognition that physician comfort and knowledge with
techniques around botulinum toxin injections lead to the best results
for patients with cervical dystonia (CD), Solstice Neurosciences,
Inc. (Solstice) has created MYOBLOC(TM) University, an online,
self-study resource that incorporates new learning technology. The
course integrates multi-dimensional, life-like animation throughout
the content -- with anatomy based on real patients with CD and actual
injection technique demonstrations with Myobloc(R) (Botulinum Toxin
Type B) Injectable Solution. The course can be accessed at
www.myoblocuniversity.com.

"MYOBLOC(TM) University is for busy physician specialists who want
to expand the scope of treatment options for their patients with
cervical dystonia, and for those seeking a comprehensive review of
the condition and the role of botulinum toxin type B," said Eric J.
Pappert, MD, assistant professor of neurology and director of the
Parkinson's Disease and Movement Disorders Program at the University
of Texas Health Science Center in San Antonio, Texas and Vice
President, Medical & Scientific Affairs of Solstice. Dr. Pappert led
the development of MYOBLOC(TM) University.

CD is often a disabling and painful movement disorder that
requires life-long management. Also known as spasmodic torticollis,
it is a condition that primarily affects the cervical area of the
neck. While the exact cause of CD is unknown, scientists believe the
problem originates in the basal ganglia area of the brain that is
instrumental in movement. The treatment goal is to lessen symptoms of
spasms, pain and impaired posture, and to improve functionality.

"A broad range of treatment options are often needed to address
the symptoms of cervical dystonia. The botulinum toxins are
considered the primary and most effective form of treatment, which
makes it critically important for physicians to be experienced with
both forms of botulinum toxin available here in the U.S.," noted Dr.
Pappert.

The multi-media content covered in MYOBLOC(TM) University includes:
-- Detailed overview of the clinical presentation and diagnosis of
CD -- with video depictions demonstrating abnormal movements and which
Muscle are involved
-- Review of currently available treatments -- oral medications, surgical
options, injections with botulinum toxin, and complementary therapies
-- Fundamentals for dosing and muscle injection techniques when using
MYOBLOC to reduce the severity of abnormal head position and neck pain
associated with CD
-- Patient case studies that illustrate the challenges and potential
solutions in managing CD patients
-- A post-test for participants to gauge their understanding of the
materials presented

Upon completing the online lesson, physicians can request
in-person training with MYOBLOC, which is available through Solstice
in a variety of venues. The company's overall goal is to support
physicians who care for CD patients -- ranging from neurologists to
physiatrists to anesthesiologists and pain management physicians.

MYOBLOC(TM) University does not offer continuing medical education
credits.

About MYOBLOC

Myobloc(R) (Botulinum Toxin Type B) Injectable Solution is
indicated for the treatment of patients with cervical dystonia to
reduce the severity of abnormal head position and neck pain
associated with cervical dystonia.

Before administering MYOBLOC, physicians should consult the full
Prescribing Information.

The most frequently reported adverse events with MYOBLOC are dry
mouth, dysphagia, dyspepsia, and injection site pain. These adverse
events are generally mild to moderate, transient, self-resolving, and
more common with higher doses.

For full Prescribing Information, please visit www.myobloc.com.

About Solstice Neurosciences, Inc.

Founded in 2004, Solstice Neurosciences, Inc. is a
biopharmaceutical company focused on the development, manufacturing,
sales and marketing of specialty products. Solstice's first product,
MYOBLOC, represents the only botulinum toxin type B currently
available to physicians and patients. MYOBLOC is sold in the United
States and approved in Canada. It is also distributed and sold in the
EU as NeuroBloc. MYOBLOC is indicated for the treatment of patients
with cervical dystonia (CD) to reduce the severity of abnormal head
position and pain associated with CD. For more information about
Solstice Neurosciences, Inc., visit www.solsticeneuro.com

Myobloc(R) and NeuroBloc(R) are registered trademarks of Solstice
Neurosciences, Inc.

Editor's Note: for access to current course offerings, users must
register on website; users can access site regardless of medical
credentials.

Web site: http://www.myoblocuniversity.com
http://www.solsticeneuro.com

ots Originaltext: Solstice Neurosciences, Inc.
Im Internet recherchierbar: http://www.presseportal.de

$story.getcontactHeadline()
Erin Evans of Cooney/Waters Group, +1-212-886-2260,
eevans@cooneywaters.com, for Solstice Neurosciences, Inc.